SageView Advisory Group’s VanEck Pharmaceutical ETF PPH Stock Holding History

SageView Advisory Group’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$2.89K	Buy	+28	New	+$2.72K	﹤0.01%	2140

Other funds holding PPH

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BCIM

British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

JSAM

J. Safra Asset Management New York $1.86B AUM 22.95% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SageView Advisory Group's PPH Position: Q4 2025 in Review

SageView Advisory Group opened a new position in VanEck Pharmaceutical ETF (PPH) in Q4 2025: 28 shares worth $2.89K. The stake represents ﹤0.01% of the portfolio and ranks #2140 among its holdings.

146 funds tracked by Wall St. Rank hold PPH as of Q4 2025.

SageView Advisory Group held 28 shares of VanEck Pharmaceutical ETF worth $2.89K as of Q4 2025.
VanEck Pharmaceutical ETF was a new SageView Advisory Group position in Q4 2025.
VanEck Pharmaceutical ETF made up ﹤0.01% of SageView Advisory Group's portfolio in Q4 2025, its #2140 holding.
146 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q4 2025.

Based on SageView Advisory Group's 13F filing for Q4 2025, filed 17 Feb 2026.